BioSpace News Archive

RAPT Therapeutics, Inc. announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020.

Burning Rock Biotech Limited announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. which will bring myChoice® tumor testing for homologous recombination deficiency, or HRD, to China.

CMIC Co., Ltd. has launched services using SUSMED, Inc.’s trial management system covering subject registration, software assignment and distribution for digital therapeutics.

The global immune health supplements market is expected to grow at a sturdy pace in the years to follow.

The drive for the photochromic lenses market comes from the growing use of lenses for protecting the eyes from ultraviolet radiation.

Rare neurological diseases are vastly underdiagnosed and most of them go untreated. Additionally, until recently there has been no specific treatments for such disorders.

The global atomic magnetometers market is expected to gain momentum during the forecast period on account of its low maintenance, initial, and labor cost.

The rise in popularity of minimally invasive procedures stands as a key factor boosting the global market for interventional Interventional Oncology Devices.

Innovent Biologics, Inc. announces that the results of the Phase I clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for neovascular age-related macular degeneration is released in e-poster at 2020 American Academy of Ophthalmology.

Increasing number of neurological diseases especially in developing economies is the key factor driving demand in the global vagus nerve stimulators market.